$CERS

CERUS CORP (CERS): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

CERUS CORP (CERS) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. 8-K false 0001020214 0001020214 2026-07-06 2026-07-06 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 6, 2

Original reporting
Published Jul 10, 2026, 8:35 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 10, 2026, 8:42 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$CERS
Neutral
medium confidence
Mentioned
$CERS
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$CERSNeutralLow
01

Why it matters

The 8-K adds specific compensation mechanics for the Executive Chairman role through May 31, 2027, including a $500,000 annual base salary, 2026 target cash bonus of 80% of base, and no annual cash bonus entitlement for 2027, plus COBRA premium reimbursement if coverage eligibility changes.

02

Market read

This is a governance and compensation update via SEC 8-K, with limited direct implications for revenue, margins, or near-term guidance.

03

What to watch

The filing does not quantify total incremental cost versus prior terms, and it omits any performance metrics tied to the 2026 target bonus, limiting how much traders can model earnings impact.

Relevance 6/10Novelty 4/10Timing: post-market after SEC 8-K filing (filed July 10, 2026)

Background

Cerus previously disclosed that William “Obi” Greenman stepped down as President and CEO and became Executive Chairman effective July 1, 2026.

Company-level read

Ticker impact

$CERSNeutralMedium confidence
Context

Cerus disclosed an 8-K amendment to Executive Chairman William “Obi” Greenman’s employment terms, including $500,000 base salary and bonus eligibility changes.

Expected impact

Low likelihood of a sustained move; any reaction is likely limited to governance sentiment and short-term expectations around executive compensation.

Evidence & confidence

The filing is a primary SEC disclosure of compensation structure tied to a role change effective July 1, 2026, with no new operational or financial guidance included.

Market effects

Minimal sector read-through; this is company-specific governance and compensation disclosure.

No clear regional spillover beyond US-listed small/mid-cap sentiment.

No direct global market relevance indicated.

Counterpoint

Investors may interpret the shift to Executive Chairman and the reduced 2027 bonus eligibility as a signal of leadership transition risk or cost-control, which could matter more than the filing suggests.

Key entities

  • Cerus Corporation

    Nasdaq-listed company filing the 8-K regarding executive departure/appointment and compensatory arrangements.

  • William “Obi” Greenman

    Former President and CEO, now Executive Chairman; amendment sets salary, bonus eligibility, and COBRA reimbursement terms.

Related articles

$CERSMed

Cerus Q3 Earnings Call Highlights

Cerus reported Q3 EMEA revenue growth of 5%, impacted by geopolitical and currency headwinds. The company's RedeS study met primary efficacy endpoints, with full analysis expected soon. Cerus reaffirmed 2026 revenue guidance of $229M-$231M and reported positive adjusted EBITDA. The company is addressing regulatory questions from the FDA and ANSM. Cerus aims for GAAP profitability and plans to refresh its shelf registration statement.

$CERSMed

Cerus: Q3 Earnings Snapshot

Cerus Corp. reported a Q3 loss of $550,000, or less than 1 cent per share, with revenue of $57.7 million. The company expects full-year revenue between $229 million and $231 million.

$CERSMedAI 8/10

Cerus' blood-safety system meets main goal in late-stage trial

Cerus Corp reported that its Intercept blood-safety technology met the main goal in a late-stage trial, showing treated red blood cells performed as well as conventional ones in transfusions. The study found no significant difference in adverse events, though some patients developed temporary antibodies. The technology is not yet FDA-approved.

$CERSMed

Cerus Corporation Announces Third Quarter 2026 Financial Results

CERUS CORP (CERS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Cerus Corporation Announces Third Quarter 2026 Financial Results Third quarter 2026 total revenue of $64.0 million; third quarter 2026 product revenue of $57.7 million, +10% Y/Y Announced positive topline Phase 3 RedeS results of the INTERCEPT Blood System for red bl

MedAI 8/10

Treated red blood cells performed no worse than conventional cells on hemoglobin gains in Cerus’ Phase 3 trial.

Cerus Corporation reported that its INTERCEPT Red Blood Cells (RBCs) met the primary efficacy endpoint in a Phase 3 trial, showing non-inferiority to conventional RBCs in adjusted hemoglobin increment. The study also met primary safety endpoints, with no significant differences in treatment-emergent adverse events between the treatment and control arms. Cerus plans to submit full study results for peer-reviewed publication and presentation at scientific meetings.